FDA staff supports a 150-milligram dose of anti-coagulant Pradaxa

09/19/2010 | Reuters

FDA reviewers said a 150-milligram, but not a 110-milligram, dose of Boehringer Ingelheim's blood thinner Pradaxa should be approved for preventing stroke in patients with atrial fibrillation. The reviewers also recommended against awarding Pradaxa a superiority claim over warfarin, an older treatment.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC